The company’s consolidated net profit surged to ₹157.17 crore in Q1FY27 from ₹58.32 crore in the year-ago quarter. Revenue from operations rose 35.6% year-on-year to ₹840.80 crore, compared with ₹620 crore in Q1FY26.
EBITDA more than doubled to ₹213.04 crore from ₹100.12 crore, while the EBITDA margin expanded to 25.3% from 16.2% a year ago.
Marksans Managing Director Mark Saldanha said Q1FY27 marked a strong start to the financial year, with quarterly EBITDA reaching a record ₹213 crore and PAT at around ₹159 crore.
The company’s UK and Europe formulation business reported its highest-ever quarterly revenue of ₹356 crore, up 74.7% year-on-year.
The company said growth in the region was supported by new product launches, continued market share gains in the UK and a strong order pipeline.
Its European expansion also gained traction during the quarter, with Netherlands-based QliniQ B.V. contributing ₹44 crore to Q1FY27 revenue.
The US and North America formulation business reported revenue of ₹377 crore, up 15.1% year-on-year. The region accounted for around 45% of consolidated revenue, with growth supported by a healthy order book and new product launches.Revenue from Australia and New Zealand rose 53.7% year-on-year to ₹88 crore, aided by portfolio expansion and new launches.
The Rest of the World (RoW) business reported revenue of ₹20 crore, down 36.8% year-on-year, although it improved 6% sequentially. The company said Middle East shipments were impacted by delays, while improving geopolitical conditions could support a recovery in the coming quarters.
Marksans’ cash balance crossed the ₹1,000-crore mark for the first time, reaching ₹1,058 crore at the end of Q1FY27, despite its recent acquisitions of QliniQ and ABCnow.
Saldanha said the strong balance sheet provides the company with the flexibility to invest in organic growth while pursuing selective inorganic opportunities.
Going ahead, Marksans plans to focus on scaling its businesses across geographies, accelerating new product launches and further strengthening its European platform.
